Phase 3 Ovarian Cancer Trial, Recruiting NCT06576375 Sponsor: Future University in Egypt Condition: Ovarian Cancer
Back to Ovarian Cancer

Phase 3 Ovarian Cancer Trial, Recruiting

NCT06576375
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Women who have been diagnosed with Polycystic Ovary Syndrome (PCOS) using a specific set of recognised diagnostic guidelines (Rotterdam 2003 or National Institute of Health criteria).
  • Women between the ages of 18 and 40.
  • Women who have been unable to conceive, whether they have never been pregnant before or have had a previous pregnancy.

Who may not be able to join:

  • People with a history of diabetes (either Type 1 or Type 2).
  • People with liver or kidney problems, inflammatory conditions, autoimmune diseases, cancer, a heart or cardiovascular event in the past three months, or an uncontrolled hormonal or metabolic condition.
  • People who have recently used certain medications, including hormonal drugs, cholesterol-lowering medications (such as statins), weight loss drugs, or medications known to affect blood sugar levels (such as acne treatments like isotretinoin, hormonal contraceptives, steroids, or anabolic steroids), unless these were stopped at least 8 weeks ago; or certain hair-growth-reducing medications, unless stopped at least 4 weeks ago.
  • People who have conditions or take medications (such as certain water tablets/diuretics) that may put them at risk of becoming dehydrated or losing too much fluid.
  • People who have had a severe allergic reaction (such as anaphylaxis, severe swelling, or serious skin reactions) to dapagliflozin or similar medications in the same drug class (SGLT2 inhibitors).
  • People currently using certain blood sugar or diabetes-related medications, including Metformin, Thiazolidinediones, GLP-1 receptor agonists, DPP-4 inhibitors, or SGLT2 inhibitors (confirm with trial site if unsure whether a current medication falls into these categories).
  • People with eating disorders such as anorexia or bulimia, or significant digestive/gastrointestinal conditions.
  • People who have previously had weight-loss (bariatric) surgery.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 21 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 01006526452

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Future University in Egypt
Registry
ClinicalTrials.gov
Start date
2 September 2024
Est. completion
1 January 2025

Where this trial is recruiting

🇪🇬 Egypt

Primary endpoints

Fertility parameters- Luteinizing hormone; Fertility parameters-Follicle-stimulating hormone; Fertility parameters-Free androgen index; Fertility parameters-Total testosterone; Transvaginal ultrasonography; Menstrual diaries

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov